Corcept Therapeutics (CORT) is moving higher as investors digest the company’s April 30, 2026 quarterly update and a raised full-year 2026 revenue outlook. Corcept increased its 2026 revenue guidance to $950 million–$1.05 billion, framing the year as a transition from a single-product revenue base to a multi-product story following its oncology launch. (sec.gov)

In the same update, Corcept pointed to two near-term demand drivers: (1) Lifyorli (relacorilant) received FDA approval in March 2026 for platinum-resistant ovarian cancer and (2) the regimen was added in April 2026 to NCCN Guidelines as a preferred regimen, which management said supported “vigorous” uptake. The combination of formal guideline inclusion and launch execution is strengthening the market’s confidence that 2026 growth will accelerate as Lifyorli revenue begins to appear in reported results. (sec.gov)

Corcept reported Q1 2026 revenue of $164.9 million versus $157.2 million in Q1 2025, while posting a net loss of $31.8 million as expenses increased to support the Lifyorli launch and growth initiatives in the core Cushing’s business. The company also said it expects to return to profitability in Q2 2026, which may be helping the stock’s tone despite the Q1 loss. (sec.gov)

Near-term attention is likely to stay on evidence of Lifyorli’s commercial traction and any updates on the company’s engagement with regulators on relacorilant in Cushing’s syndrome. Investors are also watching pipeline milestones, including timing for additional oncology data readouts later in 2026 and the planned Phase 3 start for dazucorilant in ALS. (sec.gov)